<DOC>
	<DOC>NCT01447706</DOC>
	<brief_summary>To determine whether the combination of MM-121 plus paclitaxel is more effective than paclitaxel alone</brief_summary>
	<brief_title>A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers</brief_title>
	<detailed_description>This is a multicenter, open-label, randomized, Phase II study of MM-121 in patients with platinum resistant or refractory recurrent/advanced ovarian cancers. Up to 210 patients will be randomized (2:1) to receive MM-121 plus paclitaxel or paclitaxel alone.</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Locally advanced/metastatic or recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer Received at least one prior platinum based chemotherapy regimen Platinumresistant or refractory Eligible for weekly paclitaxel Adequate liver and kidney function 18 years of age or above Evidence of any other active malignancy History of severe allergic reactions to paclitaxel or other drugs formulated in CremophorÂ®EL</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Ovarian Cancer</keyword>
	<keyword>Platinum-resistant</keyword>
	<keyword>Platinum-refractory</keyword>
	<keyword>Fallopian tube cancer</keyword>
	<keyword>Peritoneal Cancer</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>ErbB3</keyword>
	<keyword>Phase II</keyword>
	<keyword>locally advanced/metastatic or recurrent</keyword>
</DOC>